Duplex · 2 recorded sales since 2025
Listing Agent: Lori Alvarez (DRE #01794115) · Listing Office: REAL ESTATE RESOLVED · Contact: 909-227-4196 · Bought with: Jonathan Calderon · Pillar Realty · MLS #CV25051150 · Source: CRMLS
Investor’s Dream or Owner-Occupant’s Oasis – Three-Unit Opportunity! Welcome to 752 Hendricks Dr, Los Angeles—a rare multi-unit property offering incredible flexibility, financial potential, and comfort. Whether you’re an investor seeking strong rental income or a homeowner looking for a multi-generational living solution, this property is a must-see! Property Highlights: • THREE Units: Two permitted units and one unpermitted unit. • Main Residence (Unit 1 - 3 Bed / 2 Bath): • Spacious open floor plan with natural light and modern flooring • Kitchen with granite countertops and ample cabinetry (appliances not included) • Private backyard perfect for entertaining or relaxing • Second Unit (Unit 2 - 1 Bed / 1 Bath): • Separate entrance for privacy • Functional kitchen (appliances not included) • Ideal for rental income, an in-law suite, or a home office • Third Unit (Unpermitted Studio / 1 Bath): • A bonus opportunity for additional rental income (buyer to verify city/county regulations) Investment & Income Potential: • Dual-income streams with two permitted units plus the unpermitted third unit • One unit will be delivered vacant at close of escrow • Located in a high-demand rental area ensuring strong occupancy rates • Potential for value-added improvements to further increase rental income Prime Location: • Situated in a thriving Los Angeles neighborhood • Close to shopping, dining, schools, and public transportation • Offers the perfect balance of urban convenience and community charm Additional Features: * Gated property with ample parking for multiple vehicles * Separate utilities for each unit, making management easy * Low-maintenance landscaping This is a prime opportunity for investors and owner-occupants alike! Schedule a viewing today and make us an offer we can’t refuse!
Listing description from the April 2025 sale, as reported to CRMLS.